Potential use of exenatide for the treatment of obesity
Open accessAbstract
INTRODUCTION: Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in the absence of concomitant pharmacological therapy. Only bariatric surgery provides a means to increase satiety and/or decrease nutrient absorption in obese patients, in the long term. AREAS COVERED: This article reviews the available pharmacological treatments for obesity as well as the pharmacology and mechanism of action of exenatide in obese type 2 diabetic patients. EXPERT OPINION: Exenatide is a potential new candidate treatment for obesity, possibly in combination with other hormones that increase satiety (leptin) and slow gastric emptying (amylin).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many currently used anti-obesity drugs have limited clinical use because of safety or effectiveness concerns.
“However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use.”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [12]
EX has a relatively short half-life of 2.4 hours, detectable in plasma within 15 minutes after administration and still detectable 15 hours after a single subcutaneous injection >0.2 μg/kg.
“EX has a relatively short half-life of 2.4 hours, which can be detected in plasma within 15 minutes after administration, and can still be detected 15 hours after a single subcutaneous injection > 0.2 µg/kg (12).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [12]
EX is a synthetic product of exendin-4 with multiple hypoglycemic mechanisms: inhibiting glucagon release from α cells, slowing gastric emptying, decreasing appetite, and increasing glucose-dependent insulin secretion.
“As the first GLP-1R agonist approved for T2DM, EX is a new class of compound and a synthetic product of exendin-4, which is a compound naturally derived from the Gila monster and has multiple hypoglycemic mechanisms: inhibiting of glucagon release from α cells, slowing of gastric emptying, decreasing appetite and increasing glucose-dependent insulin secretion (12, 46, 47).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
Shai, I., Schwarzfuchs, D., Henkin, Y., Shahar, D. R., Witkow, S., Greenberg, I., Golan, R., Fraser, D., Bolotin, A., Vardi, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708681 · Cited by 2,143 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · see citing works
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801 · see citing works
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · see citing works
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434 · see citing works
Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394 · see citing works
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357 · see citing works
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works
Ravussin, É., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 335 · see citing works
Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324 · see citing works
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · see citing works
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · see citing works
Barnett, A. H., Burger, J., Johns, D., Brodows, R. G., Kendall, D. M., Roberts, A., & TRAUTMANN, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 240 · see citing works
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · see citing works
Navarro, M. A., de Fonseca, F. R., Álvarez, E., Chowen, J. A., Zueco, J. A., Gomez, R., Eng, J., & Blázquez, E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67051982.x · Cited by 233 · see citing works
Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J. R., Holst, J. J., & Åhrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 229 · see citing works
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works
Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · see citing works
Madsbad, S., Kielgast, U. L., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 201 · see citing works
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients
Hollander, P. A., Maggs, D. G., Ruggles, J. A., Fineman, M. S., Shen, L. Z., Kolterman, O., & Weyer, C. (2004) · Obesity Research · doi:10.1038/oby.2004.76 · Cited by 191 · see citing works
Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain
van Dijk, G., Thiele, T. E., Donahey, J. C. K., Campfield, L. A., Smith, F. J., Burn, P., Bernstein, I. L., Woods, S. C., & Seeley, R. J. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r1096 · Cited by 179 · see citing works
Amylinergic control of food intake
Lutz, T. A. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.04.001 · Cited by 175 · see citing works
Nonsurgical Management of Obesity in Adults
Eckel, R. H. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801652 · Cited by 174 · see citing works
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · see citing works
New Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 159 · see citing works
de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 157 · see citing works
The Safety of Incretin-Based Therapies—Review of the Scientific Evidence
Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works
A cohort study of acute pancreatitis in relation to exenatide use
Dore, D. D., Bloomgren, G., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01376.x · Cited by 144 · see citing works
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · see citing works
Pancreatic Amylin as a Centrally Acting Satiating Hormone
Lutz, T. A. (2005) · Current Drug Targets · doi:10.2174/1389450053174596 · Cited by 120 · see citing works
Distal Small Bowel Hormones (Correlation with Fasting Antroduodenal Motility and Gastric Emptying)
Näslund, E. B., Grybäck, P., Bäckman, L., Jacobsson, H., Juul, J. J., Theodorsson, H. E., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018806129102 · Cited by 116 · see citing works
Bergenstal, R. M., Lewin, A. J., Bailey, T. S., Chang, D., Gylvin, T., Roberts, V. L., & for the NovoLog Mix-vs.-Exenatide Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 82 · see citing works
Glucagon-like peptide-1 and satiety
van Dijk, G., Thiele, T. E., Seeley, R. J., Woods, S. C., & Bernstein, I. L. (1997) · Nature · doi:10.1038/385214a0 · Cited by 78 · see citing works
Holst, J. J., Schwartz, T. W., Na, L., Pedersen, O. B., & Beck‐Nielsen, H. (1983) · PubMed · Cited by 74 · see citing works
Taylor, K., Gurney, K., Han, J., Pencek, R., Walsh, B., & TRAUTMANN, M. E. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-9 · Cited by 64 · see citing works
The Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 53 · see citing works
RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V. (1999) · Clinical Science · doi:10.1042/cs0960335 · Cited by 47 · see citing works
Central pre-proglucagon derived peptides: Opportunities for treatment of obesity
Larsen, P., Vrang, N., & Tang-Christensen, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454775 · Cited by 24 · see citing works
Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome
González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Ramos-Zavala, M. G. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0025 · Cited by 14 · see citing works
The future of obesity medicine: where do we go from here?
Wright, S. M., & Aronne, L. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.231 · Cited by 13 · see citing works
Exenatide once weekly in type 2 diabetes mellitus
Bischoff, L. A., Jabbour, S. A., & Miller, J. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.573145 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · see citing works
Trevaskis, J. L., Sun, C., Athanacio, J., D’Souza, L. J., Samant, M. P., Tatarkiewicz, K., Griffin, P. S., Wittmer, C., Wang, Y., Teng, C. ‐., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12390 · Cited by 59 · see citing works
Ahmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 43 · see citing works
Cairano, E. S. D., Moretti, S., Marciani, P., Sacchi, V. F., Castagna, M., Davalli, A. M., Folli, F. B., & Perego, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25176 · Cited by 44 · see citing works
Self-citationMechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 32 · see citing works
Self-citationPATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 32 · see citing works
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30 · see citing works
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 30 · see citing works
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Detroja, J., Patel, K. N., Gandhi, T. R., Patel, K. V., Bahekar, R. H., & Jain, M. R. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71074-0 · Cited by 28 · see citing works
Current Updates in the Medical Management of Obesity
Khan, A. U., Raza, S., Khan, Y., Aksoy, T., Khan, M., Weinberger, Y., & Goldman, J. M. (2012) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221412800604644 · Cited by 25 · see citing works
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 26 · see citing works
Roth, E., Benoit, S., Quentin, B., Lam, B., Will, S., Ma, M. K. L., Heeley, N., Darwish, T., Shrestha, Y., Gribble, F. M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101118 · Cited by 21 · see citing works
Weight Loss Is Still an Essential Intervention in Obesity and its Complications: A Review
Xiao, J., & Yang, W. (2012) · Journal of Obesity · doi:10.1155/2012/369097 · Cited by 19 · see citing works
Tawfik, M. K., Badran, D. I., Keshawy, M. M., Makary, S., & Abdo, M. (2022) · Archives of Medical Science · doi:10.5114/aoms/158534 · Cited by 14 · see citing works
Patel, K. N., Joharapurkar, A. A., PATEL, V. G., Kshirsagar, S. G., Bahekar, R. H., Srivastava, B. K., & Jain, M. R. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0310 · Cited by 13 · see citing works
Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition
Agcakaya, E., Mutlu, H. H., Erbakan, A. N., & Sargın, M. (2023) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2023.03.308 · Cited by 9 · see citing works
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 6 · see citing works
Therapeutic Repurposing of Antidiabetic Drugs in Diabetes-associated Comorbidities
Pathak, K., Pathak, M. P., Saikia, R., Gogoi, U., Das, R. J., Patowary, P., Kaishap, P. P., Bordoloi, S., Das, J., Sarma, H., et al. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230516150404 · Cited by 5 · see citing works
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Peptide Science · doi:10.1002/9781119824701.ch09 · Cited by 4 · see citing works
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 2 · see citing works
Xu, M., Zhang, P., Lv, W., Chen, Y., Chen, M., Leng, Y., Hu, T., Wang, K., Zhao, Y., Shen, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127003 · Cited by 1 · see citing works
Sezer, G. E., & Mert, M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6332117 · Cited by 1 · see citing works
Preguntas y respuestas sobre aspectos generales del tratamiento farmacológico en el paciente obeso
Rodríguez, J. H., Puig, M. E. L., & Elías-Calles, L. C. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
Rodríguez, J. H., & Puig, M. E. L. (2013)
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
de Antioquia, U., Rojas-Henao, N. A., Granados, J., & de Antioquia, U. (2018) · CES Medicina · doi:10.21615/cesmedicina.32.1.3
Natche, J., Lerma, R. O., Hanumantharayudu, S. K., Surendraiah, P. K. M., Rahman, S., Rahman, F., Shah, S., Bhatta, M., Green, S. R., Sultana, M., et al. (2026) · Cureus · doi:10.7759/cureus.102516
- Authors
- Folli, F., & Guardado Mendoza, R.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- University of Guanajuato, Division of Health Sciences, Department of Medicine and Nutrition, León, Gto, México
- ORCID
- Folli, Franco
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2011-10-24
- Volume
- 20
- Issue
- 12
- Pages
- 1717-1722
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- PMC
- PMC3495586
- OpenAlex
- W1968389922
- Cited by
- 26
- References
- 52
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 1 · 2020: 2 · 2018: 1 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080148)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- exenatide, obesity treatment, GLP-1 receptor agonists, satiety hormones, leptin, amylin, gastric emptying, type 2 diabetes, bariatric surgery
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Eating, Humans, Hypoglycemic Agents, Obesity, Peptides, Venoms, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
